Colorectal Carcinoma
: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients
United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined
Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.
Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment
Xilio Therapeutics, Vilastobart, Anti-CTLA-4, Colorectal Cancer, Stock Price, Phase 2 Data
Merck’s Keytruda and LAG-3 Antibody Combo Fails in Phase 3 Colorectal Cancer Trial
Keytruda, LAG-3, colorectal cancer, Phase 3 trial, Merck & Co., favezelimab, pembrolizumab, KEYFORM-007
Exact Sciences Advances Toward FDA Submission with Promising Blood-Based Colorectal Cancer Screening Test
Exact Sciences, Blood-Based Colorectal Cancer Screening, ESMO 2024, FDA Submission, Colorectal Cancer Detection, Advanced Precancerous Lesions
NuCana Terminates Mid-Stage Colorectal Cancer Trial Due to Disappointing Results
NuCana, colorectal cancer, chemotherapy derivative, mid-stage trial, disappointing results
NuCana’s Chemotherapy Replacement Fails to Improve Survival in Phase II Trial
NuCana, chemotherapy replacement, Phase II trial, progression-free survival, colorectal cancer, NUC-3373
Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo
Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff
FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search
Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership
FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer
Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras